Patents-Review.com
ClassID:

110773 ⎘

C12N2760/14234 - CPC Classification

Classification description:

ssRNA viruses negative-sense; Details; Filoviridae; Marburgvirus, e.g. lake Victoria marburgvirus Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Recent Application in this class:
#1
20260041757
2026-02-12

THERMOSTABLE MUCOSAL VACCINE COMPOSITIONS AND METHODS

 #2
20240293526
2024-09-05

EBOLAVIRUS AND MARBURGVIRUS VACCINES

 #3
20240156940
2024-05-16

REPLICATION-DEFICIENT MODIFIED VACCINIA ANKARA (MVA) EXPRESSING MARBURG VIRUS GLYCOPROTEIN (GP) AND MATRIX PROTEIN (VP40)

 #4
20230293664
2023-09-21

consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

 #5
20220152190
2022-05-19

Replication-deficient modified vaccinia Ankara (MVA) expressing glycoprotein (GP) and matrix protein (VP40)

 #6
20220088170
2022-03-24

Methods and compositions for inducing protective immunity against filovirus infection

 #7
20210299241
2021-09-30

Reverse peptide vaccine

 #8
20210292371
2021-09-23

Stabilized Filovirus glycoprotein trimers

 #9
20200392188
2020-12-17

Recombinant human replication-deficient adenovirus comprising a modified nucleic acid encoding the Marburg virus envelope glycoprotein

 #10
20200390880
2020-12-17

Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

 #11
20200268872
2020-08-27

Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding filovirus immunogens

 #12
20200038500
2020-02-06

Methods and compositions for inducing protective immunity against filovirus infection

 #13
20190290751
2019-09-26

Marburgvirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

 #14
20190224301
2019-07-25

Methods and compositions for inducing protective immunity against a marburg virus infection

 #15
20190117758
2019-04-25

Replication-deficient modified vaccinia Ankara (MVA) expressing Ebola virus glycoprotein (GP) and matrix protein (VP40)

 #16
20180344840
2018-12-06

Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

 #17
20180135075
2018-05-17

Recombinant adenovirus expressing two transgenes with a bidirectional promoter

 #18
20170340721
2017-11-30

Methods and compositions for enhancing immune responses

 #19
20170326225
2017-11-16

EBOLAVIRUS AND MARBURGVIRUS VACCINES

 #20
20170304427
2017-10-26

Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogenic compositions and methods of use

 #21
20170290904
2017-10-12

Methods and compositions for inducing protective immunity against filovirus infection

 #22
20170165350
2017-06-15

Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

 #23
20170089920
2017-03-30

Method and composition for determining specific antibody responses to species of filovirus

 #24
20170065702
2017-03-09

METHODS OF MODULATING AN IMMUNE RESPONSE

 #25
20150335726
2015-11-26

Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same

 #26
20140212434
2014-07-31

Multivalent vaccines for rabies virus and filoviruses

 #27
20120136142
2012-05-31

Adjuvant

 #28
20120065371
2012-03-15

Recombinant proteins from filoviruses and their use

 #29
20110217328
2011-09-08

COMPOSITIONS AND METHODS FOR TREATING EBOLA VIRUS INFECTION

 #30
20110014227
2011-01-20

Pre-or post-exposure treatment for filovirus or arenavirus infection

 #31
20100285055
2010-11-11

Activation of natural killer (NK) cells and methods of use

 #32
20070082011
2007-04-12

Drosophila cell lines producing recombinant secretable filovirus surface glycoproteins lacking the membrane spanning domain

 #33
20060193872
2006-08-31

Recombinant vesicular stomatitis virus vaccines for viral hemorrhagic fevers

 #34
20060099609
2006-05-11

Activation of natural killer (NK) cells and methods of use

 #35
20050266023
2005-12-01

Generation of virus-like particles and use as panfilovirus vaccine